291 related articles for article (PubMed ID: 21134982)
21. Comorbidities and frailty predict outcome of patients with myelodysplastic syndromes. Should we integrate them in novel prognostic scoring systems?
Thomopoulos TP; Pappa V; Papageorgiou SG
J Geriatr Oncol; 2021 Sep; 12(7):1122-1129. PubMed ID: 33771514
[TBL] [Abstract][Full Text] [Related]
22. Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes.
Bammer C; Sperr WR; Kemmler G; Wimazal F; Nösslinger T; Schönmetzler A; Krieger O; Pfeilstöcker M; Valent P; Stauder R
J Geriatr Oncol; 2014 Jul; 5(3):299-306. PubMed ID: 24636334
[TBL] [Abstract][Full Text] [Related]
23. The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany.
Gattermann N; Kündgen A; Kellermann L; Zeffel M; Paessens B; Germing U
Eur J Haematol; 2013 Dec; 91(6):473-82. PubMed ID: 24102637
[TBL] [Abstract][Full Text] [Related]
24. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.
Naqvi K; Sasaki K; Montalban-Bravo G; Alfonso Pierola A; Yilmaz M; Short N; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Kanagal-Shamanna R; Patel K; Soltysiak KA; Kantarjian HM; Garcia-Manero G
Cancer; 2019 Jul; 125(13):2233-2241. PubMed ID: 30861111
[TBL] [Abstract][Full Text] [Related]
25. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
26. Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study.
Rozema J; Hoogendoorn M; Kibbelaar R; van den Berg E; Veeger N; van Roon E
Blood Adv; 2021 Mar; 5(5):1344-1351. PubMed ID: 33656535
[TBL] [Abstract][Full Text] [Related]
27. Overview of myelodysplastic syndromes.
Beris P; Georgiou G
Semin Hematol; 2012 Oct; 49(4):287-94. PubMed ID: 23079058
[TBL] [Abstract][Full Text] [Related]
28. Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults.
Fega KR; Abel GA; Motyckova G; Sherman AE; DeAngelo DJ; Steensma DP; Galinsky I; Wadleigh M; Stone RM; Driver JA
J Geriatr Oncol; 2015 Jul; 6(4):288-98. PubMed ID: 26073533
[TBL] [Abstract][Full Text] [Related]
29. MDS-Comorbidity Index using register data has prognostic impact in Swedish MDS patients.
Larfors G; Moreno Berggren D; Garelius H; Nilsson L; Rasmussen B; Hellström-Lindberg E; Ejerblad E
Leuk Res; 2023 Nov; 134():107386. PubMed ID: 37690322
[TBL] [Abstract][Full Text] [Related]
30. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
31. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
32. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.
Zeidan AM; Sekeres MA; Garcia-Manero G; Steensma DP; Zell K; Barnard J; Ali NA; Zimmerman C; Roboz G; DeZern A; Nazha A; Jabbour E; Kantarjian H; Gore SD; Maciejewski JP; List A; Komrokji R;
Leukemia; 2016 Mar; 30(3):649-57. PubMed ID: 26464171
[TBL] [Abstract][Full Text] [Related]
33. Myelodysplastic syndromes: diagnosis and staging.
Malcovati L; Nimer SD
Cancer Control; 2008 Oct; 15 Suppl():4-13. PubMed ID: 18813205
[TBL] [Abstract][Full Text] [Related]
34. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.
Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW
Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029
[TBL] [Abstract][Full Text] [Related]
35. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
[TBL] [Abstract][Full Text] [Related]
36. Proposed score for survival of patients with myelodysplastic syndromes.
Sperr WR; Kundi M; Wimazal F; Nösslinger T; Schönmetzler-Makrai A; Stauder R; Krieger O; Neukirchen J; Germing U; Pfeilstöcker M; Valent P
Eur J Clin Invest; 2013 Nov; 43(11):1120-8. PubMed ID: 24102333
[TBL] [Abstract][Full Text] [Related]
37. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
[TBL] [Abstract][Full Text] [Related]
38. Impact of age and comorbidity in myelodysplastic syndromes.
Stauder R; Nösslinger T; Pfeilstöcker M; Sperr WR; Wimazal F; Krieger O; Valent P
J Natl Compr Canc Netw; 2008 Oct; 6(9):927-34. PubMed ID: 18926101
[TBL] [Abstract][Full Text] [Related]
39. The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients.
Stauder R
Ann Hematol; 2012 Sep; 91(9):1333-43. PubMed ID: 22547053
[TBL] [Abstract][Full Text] [Related]
40. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].
Wang XQ;
Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]